Cerity Partners
KRYS icon

Cerity Partners’s Krystal Biotech KRYS Stock Holding History

Cerity Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,361
Closed -$336K – 3329
2025
Q4 		$336K Buy
+1,361
New +$286K ﹤0.01% 2345
2024
Q4 		– Sell
-1,542
Closed -$281K – 2524
2024
Q3 		$281K Buy
+1,542
New +$297K ﹤0.01% 2101

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cerity Partners's KRYS Position: Q1 2026 in Review

Cerity Partners sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,361 shares — an estimated $336K sold.

Cerity Partners first reported a position in KRYS in Q3 2024 and held it in 2 quarters. The position peaked at $336K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Cerity Partners reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Cerity Partners sold 1,361 Krystal Biotech shares in Q1 2026, an estimated $336K.
  • Cerity Partners first reported a position in Krystal Biotech in Q3 2024 and held it in 2 quarters.
  • Cerity Partners's Krystal Biotech position peaked at $336K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.